Duopharma Biotech Berhad Yönetim

Yönetim kriter kontrolleri 4/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Leonard bin Abdul Shatar

İcra Kurulu Başkanı

RM 2.5k

Toplam tazminat

CEO maaş yüzdesi	47.8%
CEO görev süresi	17yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2yrs
Yönetim Kurulu ortalama görev süresi	6.8yrs

Son yönetim güncellemeleri

Recent updates

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Aug 27

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Apr 04

Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price

Feb 17

These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Oct 21

Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Aug 18

Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Aug 07

Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year

Mar 28

Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Mar 27

We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings

Nov 26

Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021

Nov 25

Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005

Aug 20

Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

May 22

Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend

Apr 13

Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?

Jan 12

CEO Tazminat Analizi

Leonard bin Abdul Shatar'un ücretlendirmesi Duopharma Biotech Berhad'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	RM 56m
Jun 30 2024	n/a	n/a	RM 49m
Mar 31 2024	n/a	n/a	RM 45m
Dec 31 2023	RM 3k	RM 1k	RM 53m
Sep 30 2023	n/a	n/a	RM 61m
Jun 30 2023	n/a	n/a	RM 69m
Mar 31 2023	n/a	n/a	RM 72m
Dec 31 2022	RM 2m	RM 1m	RM 70m
Sep 30 2022	n/a	n/a	RM 69m
Jun 30 2022	n/a	n/a	RM 69m
Mar 31 2022	n/a	n/a	RM 68m
Dec 31 2021	RM 2m	RM 1m	RM 66m
Sep 30 2021	n/a	n/a	RM 66m
Jun 30 2021	n/a	n/a	RM 63m
Mar 31 2021	n/a	n/a	RM 63m
Dec 31 2020	RM 2m	RM 924k	RM 59m
Sep 30 2020	n/a	n/a	RM 54m
Jun 30 2020	n/a	n/a	RM 55m
Mar 31 2020	n/a	n/a	RM 54m
Dec 31 2019	RM 2m	RM 882k	RM 55m
Sep 30 2019	n/a	n/a	RM 58m
Jun 30 2019	n/a	n/a	RM 55m
Mar 31 2019	n/a	n/a	RM 51m
Dec 31 2018	RM 1m	RM 876k	RM 48m

Tazminat ve Piyasa: Leonard 'nin toplam tazminatı ($USD 563.18 ), MY pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 123.47K ).

Tazminat ve Kazançlar: Leonard 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Leonard bin Abdul Shatar (59 yo)

17yrs

Görev süresi

RM 2,533

Tazminat

Encik Ariff bin Abdul Shatar, also known as Leonard, has been Group Managing Director of Duopharma Biotech Berhad (alternate name Duopharma Biotech Bhd) since December 28, 2017. Encik bin Abdul Shatar serv...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ariff bin Abdul Shatar	Group MD & Executive Director	17yrs	RM 2.53k	Veri yok
Wu Chek	Chief Financial Officer	12.5yrs	Veri yok	0.000010% MYR 121.2
Wan Bin Wan Abdul Majid	Chief Executive Officer of Group Operations	less than a year	Veri yok	Veri yok
Ibrahim Salleh	Chief Legal Officer & Group Company Secretary	7.1yrs	Veri yok	Veri yok
Sabrina Haron	Chief Compliance Officer	1.5yrs	Veri yok	Veri yok
Krisnakumara Reddi	Chief Manufacturing & Sustainability Officer	2.3yrs	Veri yok	0.00030% MYR 3.6k
Shamsul Bin A. Iahad	Chief Consumer Healthcare Officer	less than a year	Veri yok	Veri yok
Wan Ahmad Bin Wan Mohd. Salleh	Group Head of Risk Management & Integrity	2yrs	Veri yok	Veri yok
Priya Asokan	Chief Innovation Officer	less than a year	Veri yok	Veri yok

2.0yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: DPHARMA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ariff bin Abdul Shatar	Group MD & Executive Director	7.1yrs	RM 2.53k	Veri yok
Nik Binti Nik Mohamed Shihabuddin	Independent Non-Executive Director	less than a year	Veri yok	Veri yok
Razalee Bin Amin	Independent Non-Executive Director	8.6yrs	RM 130.80k	Veri yok
Mohd Bin Mohd Yunus	Non Independent Non Executive Director	6.8yrs	RM 146.40k	0.0026% MYR 31.9k
Nik Bin Nik Hassan	Independent Non-Executive Director	7.1yrs	RM 143.80k	Veri yok
Zaki Bin Mohamad Zaher	Independent Non-Executive Director	5.3yrs	RM 135.40k	Veri yok
Zaiton Binti Jamaluddin	Independent Non Executive Director	8.3yrs	RM 143.80k	Veri yok
Eisah Binti Rahman	Senior Independent Non-Executive Director	8.2yrs	RM 141.40k	Veri yok
Kartini Binti Abdul Manaf	Non-Independent & Non-Executive Chairman	1.6yrs	RM 76.70k	Veri yok
Muhammad Bin Ismail	Non Independent & Non Executive Alternate Director	1.4yrs	Veri yok	Veri yok
Mohd Bin Mohd Arshad	Non-Independent & Non-Executive Director	less than a year	Veri yok	Veri yok

6.8yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: DPHARMA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.8 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/10 01:23
Gün Sonu Hisse Fiyatı	2025/01/10 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Duopharma Biotech Berhad 10 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Khir Goh	AmInvestment Bank Berhad
Kok Chee	AmInvestment Bank Berhad
Hsien Jin Lam	CGS International

Duopharma Biotech Berhad Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Duopharma Biotech Berhad Announces Retirement of Tan Sri, Datin Paduka Siti Sa'diah Binti Sh Bakir as Non-Independent and Non-Executive Chairman

Duopharma Biotech Berhad, Annual General Meeting, Jun 06, 2024

Duopharma Biotech Berhad Announces the Resignation of Puan Amizar Binti Mizuar as Non Independent and Non Executive Director

Duopharma Biotech Berhad Appoints ENCIK MUHAMMAD SHUKRI BIN ISMAIL as Non Independent and Non Executive Alternate Director

Duopharma Biotech Berhad Announces Re-Designation of Dato' Eisah Binti A. Rahman, Member of Nomination and Remuneration Committee as Independent and Non-Executive Chairman of Nomination and Remuneration Committee, Date of Change 1 June 2023

Duopharma Biotech Berhad Announces Retirement of Dato' Mohamad Kamarudin Bin Hassan as Independent and Non-Executive Member of Risk Committee

Recent updates

Third quarter 2024 earnings released: EPS: RM0.016 (vs RM0.009 in 3Q 2023)

Second quarter 2024 earnings released: EPS: RM0.017 (vs RM0.013 in 2Q 2023)

Duopharma Biotech Berhad Announces Retirement of Tan Sri, Datin Paduka Siti Sa'diah Binti Sh Bakir as Non-Independent and Non-Executive Chairman

New minor risk - Profit margin trend

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Duopharma Biotech Berhad, Annual General Meeting, Jun 06, 2024

Duopharma Biotech Berhad Announces the Resignation of Puan Amizar Binti Mizuar as Non Independent and Non Executive Director

Consensus EPS estimates fall by 11%

Upcoming dividend of RM0.018 per share

Full year 2023 earnings released: EPS: RM0.055 (vs RM0.074 in FY 2022)

Now 20% undervalued

Third quarter 2023 earnings released: EPS: RM0.009 (vs RM0.017 in 3Q 2022)

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Price target decreased by 8.3% to RM1.63

Second quarter 2023 earnings released: EPS: RM0.013 (vs RM0.017 in 2Q 2022)

Duopharma Biotech Berhad Declares Interim Dividend for the 30 June 2023, Payable on 22 September 2023

Duopharma Biotech Berhad Appoints ENCIK MUHAMMAD SHUKRI BIN ISMAIL as Non Independent and Non Executive Alternate Director

Duopharma Biotech Berhad Announces Re-Designation of Dato' Eisah Binti A. Rahman, Member of Nomination and Remuneration Committee as Independent and Non-Executive Chairman of Nomination and Remuneration Committee, Date of Change 1 June 2023

Duopharma Biotech Berhad Announces Retirement of Dato' Mohamad Kamarudin Bin Hassan as Independent and Non-Executive Member of Risk Committee

Full year 2022 earnings: EPS and revenues miss analyst expectations

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Upcoming dividend of RM0.018 per share at 1.5% yield

Full year 2022 earnings released: EPS: RM0.074 (vs RM0.071 in FY 2021)

Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price

Price target increased to RM1.81

Insufficient new directors

Third quarter 2022 earnings released: EPS: RM0.017 (vs RM0.018 in 3Q 2021)

Insufficient new directors

These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Insufficient new directors

Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Second quarter 2022 earnings released: EPS: RM0.017 (vs RM0.016 in 2Q 2021)

Duopharma Biotech Berhad Announces an Interim Dividend, Payable on 14 September 2022

Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Duopharma Biotech Berhad, Annual General Meeting, Jun 21, 2022

Now 21% undervalued after recent price drop

Full year 2021 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of RM0.018 per share

Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year

Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Full year 2021 earnings: EPS and revenues miss analyst expectations

Duopharma Biotech Declares Second Interim Dividend in Respect of the Financial Year Ended 31 December 2021

We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings

Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021

Price target decreased to RM1.97

Third quarter 2021 earnings released: EPS RM0.018 (vs RM0.015 in 3Q 2020)

Investor sentiment deteriorated over the past week

Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005

Second quarter 2021 earnings released: EPS RM0.022 (vs RM0.022 in 2Q 2020)

Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

Full year 2020 earnings released: EPS RM0.085 (vs RM0.082 in FY 2019)

Upcoming dividend of RM0.06 per share

Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend

Price target decreased to RM3.10

A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Investor sentiment deteriorated over the past week

New 90-day low: RM3.03

Full year 2020 earnings released: EPS RM0.085 (vs RM0.082 in FY 2019)

Revenue behind estimates

Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly

Do Institutions Own Duopharma Biotech Berhad (KLSE:DPHARMA) Shares?

Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?

Price target raised to RM2.45

Government of Malaysia, Biocon Sdn. Bhd. and Duopharma Biotech Berhad Extends the Contract Period Under the Agreement One Year Effective from 2 December 2020 Until 1 December 2021

Duopharma Biotech Berhad Announces Temporary Closure of Registered Office

First half earnings released